Jefferies upgrades ImmunityBio stock to Strong Buy

Published on 10/02/2026 at 18:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven analysts set a USD 14.20 average target. ImmunityBio stock cost EUR 9.21 on October 2, 2026, plus 11.77 percent versus EUR 8.24.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio stock (ISIN US45256X1037) was trading at EUR 9.21 at Lang & Schwarz on October 2, 2026, up 11.77 percent versus the prior close of EUR 8.24. The latest rating change came from Jefferies, which upgraded ImmunityBio to a Strong Buy rating in a research note dated September 25, 2026, according to MarketBeat.

Jefferies changes the rating

The upgrade adds a fresh analyst signal to ImmunityBio's commercial expansion story. MarketBeat reported on October 1, 2026, that one analyst held a Strong Buy rating, five had Buy ratings and one had a Sell rating, producing a Moderate Buy consensus and a USD 14.20 average target.

The target is materially above the latest US market quote cited by MarketBeat, but the research summary also shows that the rating mix is not unanimous. The same report identified a USD 15.00 target from HC Wainwright and a USD 12.00 target from BTIG, both dated earlier in 2026, according to MarketBeat.

Revenue growth meets a loss

ImmunityBio's operating progress is concentrated in ANKTIVA, its lead immunotherapy. The company reported record net product revenue of USD 50.70 million in the second quarter of 2026, up 92.00 percent year over year, while first-half 2026 revenue reached USD 94.80 million, up 121.00 percent year over year, on its investor-relations page at ImmunityBio.

The counterweight is profitability. MarketBeat reported that second-quarter 2026 earnings per share came to minus USD 0.22, missing the consensus loss of minus USD 0.08 by USD 0.14, even as revenue of USD 51.24 million exceeded the USD 49.70 million consensus estimate.

IBRX price gains after-hours

At Lang & Schwarz, the stock was trading at EUR 9.21 on October 2, 2026 at 6:03 p.m. CEST, plus 11.77 percent against the prior close of EUR 8.24. ImmunityBio's primary listing is NASDAQ, where MarketBeat identified a one-year range of USD 1.95 to USD 12.43 and a market capitalization of USD 9.84 billion on October 1, 2026.